Our team is ready to serve as your trusted guide from molecule to market.
Emergent CDMO is experienced in a wide range of platforms and technologies including, mammalian, microbial, viral, plasma, and advanced therapies to support preclinical through commercial manufacturing. Our team is ready to serve as your trusted guide from molecule to market.
More Videos by Emergent Contract Development & Manufacturing Services
Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies, which began in February 2021.
Lenzilumab™ is currently in a Phase 3 clinical trial evaluating patients hospitalized with COVID-19. Humanigen intends to file for EUA first quarter of 2021.